SCHEMBL6501627

SCHEMBL6501627

Cc1ccc(-c2ccc(C(=O)NC3CC4CNC3C4)o2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 1/20 0.43
ALDH1A1 P00352 8/20 0.43
KDM4E B2RXH2 6/20 0.43
MAPT P10636 3/20 0.43
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
GAA P10253 3/20 0.42
MGAM O43451 1/20 0.42
SI P14410 1/20 0.42
MGAM2 Q2M2H8 1/20 0.42
NPC1 O15118 4/20 0.42
RAB9A P51151 4/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
HPGD P15428 4/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
LMNA P02545 3/20 0.41
GPR55 Q9Y2T6 1/20 0.41
POLB P06746 2/20 0.40
PDE4B Q07343 4/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6500809 0.90 NPC1 (0.43) ALDH1A1KDM4EMAPTKMT2AMEN1
SCHEMBL6500577 0.89 MAPKAPK2 (0.45) MMP13ALDH1A1KDM4EMAPTKMT2A
SCHEMBL6497293 0.89 NPC1 (0.56) MMP13ALDH1A1KDM4EMAPTNPC1
SCHEMBL6489260 0.89 ALDH1A1 (0.49) ALDH1A1KDM4EMAPTKMT2AMEN1
SCHEMBL6500583 0.89 NPC1 (0.42) ALDH1A1KDM4EMAPTKMT2AMEN1
SCHEMBL6488167 0.88 S1PR4 (0.43) ALDH1A1KDM4EMAPTKMT2AMEN1
SCHEMBL6496636 0.87 SLC9A1 (0.45) ALDH1A1KDM4EMAPTKMT2AMEN1
SCHEMBL6496009 0.87 MEN1 (0.49) MMP13ALDH1A1KDM4EMAPTKMT2A
SCHEMBL6486768 0.83 HPGD (0.50) ALDH1A1MAPTNPC1RAB9AL3MBTL1
SCHEMBL6490768 0.82 MAPKAPK2 (0.41) ALDH1A1KDM4EMAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US claimed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US claimed
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US disclosed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease MALT1, WFS1, NR5A1 MMP13 4148/4885ALDH1A1 625/4885KDM4E 2799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.